Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-09 pm EDT			5-day change	1st Jan Change
113.24 ^USD	+1.96%		+1.55%	+22.59%

05:40am	Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	MT
Jul. 09	Major deals involving U.S. drugmakers and biotechs over the past decade	RE

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition

Published on 03/22/2024 at 09:56, updated on 03/22/2024 at 10:02

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Gilead Sciences, Inc.

Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket	05:40am	MT
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Gilead finalizes agreement with global fund to accelerate access to Lenacapavir	Jul. 09	RE
Tariff Drama, Minimal Market Reaction	Jul. 09
Gilead Sciences, Inc. Finalizes Agreement with the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for Up to Two Million People in Primarily Low- and Lower- Middle-Income Countries	Jul. 09	CI
Gilead Sciences Signs Agreement With Global Fund to Fight AIDS to Supply HIV Prevention Drug Lenacapavir	Jul. 09	MT
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries	Jul. 09	RE
RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating	Jul. 07	MT
Gilead Sciences Insider Sold Shares Worth $1,104,484, According to a Recent SEC Filing	Jul. 02	MT
Assembly Biosciences Doses First Participant in Phase 1B Portion of Phase 1A/B Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor Abi-1179	Jun. 30	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 3000 Growth Index	Jun. 30	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 1000 Growth-Defensive Index	Jun. 30	CI
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	Jun. 30	RE
Assembly Biosciences Says First Participant Dosed in Phase 1b Study of HSV Drug ABI-1179	Jun. 30	MT
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 1000 Growth Index	Jun. 30	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 3000E Growth Index	Jun. 30	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell Top 200 Growth Index	Jun. 30	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 3000 Growth Benchmark	Jun. 29	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 3000E Growth Benchmark	Jun. 29	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell Top 200 Growth Benchmark	Jun. 29	CI
Gilead Sciences, Inc.(NasdaqGS:GILD) added to Russell 1000 Growth Benchmark	Jun. 29	CI
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Gilead shares rise after US top court ruling on preventive coverage	Jun. 27	RE
Pharos Energy Names New Nonexecutive Chair	Jun. 26	MT
Assembly Biosciences Reports Positive Topline Results from Phase 1B Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B	Jun. 25	CI

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

Aug. 04 - Q2 2025 Earnings Release (Projected)

More about the company